First Human Study of SBT777101 in Rheumatoid Arthritis by Sonoma Biotherapeutics
Sonoma Biotherapeutics is conducting the first human trial of SBT777101 for rheumatoid arthritis, focusing on safety and effects.
Asset / Drug
Drug and asset intelligence for SBT777101 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Monoclonal Antibody
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.